logo
logo

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing To Advance The Development Of Novel, Targeted Treatment For Hypertension

Jun 08, 2022•about 3 years ago

Amount Raised

$118 Million

Round Type

series b

Philadelphia

Description

Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension, today announced the completion of an oversubscribed and up-sized $118 million Series B financing.

Company Information

Company

Mineralys Therapeutics

Location

Philadelphia, Pennsylvania, United States

About

Headquartered in Philadelphia, PA, Mineralys Therapeutics, Inc. is a private, clinical-stage biopharmaceutical company, founded by Catalys Pacific, and is committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension. For more information, please visit https://mineralystx.com/.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech